Pyridostigmine Bromide — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.5-3 mg/kg	q8-12h	Duration: Long-term, as needed Notes: Start at low end and titrate to effect. Adjust dose based on clinical response and adverse effects. For congenital myasthenia, may require higher doses.
Dog	IV	0.01-0.04 mg/kg	Slow IV, as needed	Duration: For reversal of neuromuscular blockade, administer with atropine (0.04 mg/kg IV). Notes: Use with caution; monitor heart rate and respiratory function.
Cat	PO	0.25-1 mg/kg	q8-12h	Duration: Long-term, as needed Notes: Use cautiously; cats are sensitive to cholinergic effects.
Horse	PO	0.5-1 mg/kg	q8-12h	Duration: As needed Notes: For myasthenia gravis, titrate to effect. For ileus, use lower doses.
Horse	IV	0.01-0.02 mg/kg	Slow IV, as needed	Duration: For reversal of neuromuscular blockade, with atropine. Notes: Monitor closely.
Cattle	PO	0.5-1 mg/kg	q8-12h	Duration: As needed Notes: Not commonly used; use with caution.
Small Ruminants	PO	0.5-1 mg/kg	q8-12h	Duration: As needed Notes: Not commonly used; use with caution.
Rabbit	PO	0.5-1 mg/kg	q8-12h	Duration: As needed Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications

Myasthenia gravis
Reversal of non-depolarizing neuromuscular blockade (adjunct to atropine)

Dog (Canine)

Myasthenia gravis (acquired and congenital)
Reversal of non-depolarizing neuromuscular blockade (with atropine)

Cat (Feline)

Myasthenia gravis (rarely used, but may be used off-label)

Horse (Equine)

Myasthenia gravis (rare)
Postoperative ileus (off-label)
Reversal of non-depolarizing neuromuscular blockade (with atropine)

Pharmacology & Mechanism of Action

Drug Class: Cholinesterase Inhibitor | Pharmacological Group: Parasympathomimetic (Anticholinesterase)

Mechanism of Action: Pyridostigmine bromide is a reversible acetylcholinesterase inhibitor. It binds reversibly to the anionic and esteratic sites of acetylcholinesterase, preventing the hydrolysis of acetylcholine. This results in increased concentrations of acetylcholine at cholinergic synapses, enhancing cholinergic neurotransmission. In the context of myasthenia gravis, it improves neuromuscular transmission by increasing the availability of acetylcholine at the motor endplate, thereby improving muscle strength. It also stimulates muscarinic and nicotinic receptors, leading to parasympathetic effects.

Pharmacodynamics: Pyridostigmine produces its therapeutic effects by inhibiting acetylcholinesterase, leading to accumulation of acetylcholine. This enhances cholinergic activity at both muscarinic and nicotinic receptors. In myasthenia gravis, it improves muscle strength and reduces fatigue. It also increases gastrointestinal motility, secretions, and bronchial secretions. The onset of action after oral administration is typically 30-60 minutes, with peak effects at 1-2 hours. Duration of action is approximately 3-6 hours, but can vary by species.

⚡ Pharmacokinetics Summary

Absorption: Pyridostigmine is poorly absorbed from the gastrointestinal tract. Oral bioavailability is approximately 10-20% in most species. Absorption is variable and may be affected by food. Onset of action after oral administration is 30-60 minutes.

Distribution: Pyridostigmine is distributed widely in body tissues, but it does not cross the blood-brain barrier to a significant extent. It crosses the placenta in small amounts. Volume of distribution is moderate.

Metabolism: Pyridostigmine is metabolized in the liver and also undergoes hydrolysis by acetylcholinesterase. The major metabolite is 3-hydroxy-N-methylpyridinium.

Excretion: Pyridostigmine is excreted primarily in the urine, both as unchanged drug and as metabolites. Renal excretion involves both glomerular filtration and active tubular secretion. In animals with renal impairment, dose adjustment may be necessary.

Half-Life: Dog: 1-2 hours; Horse: 1.5 hours; Cat: 1-2 hours (estimated); Cattle: 1-2 hours (estimated).

Bioavailability: Oral bioavailability is low, approximately 10-20% in dogs and other species. Parenteral administration provides complete bioavailability.

Protein Binding: Low protein binding, approximately 10-20%.

Available Formulations & Strengths

Oral Tablet 60 mg, 180 mg (extended-release) (PO)

Oral Syrup 60 mg/5 mL (PO)

Injectable Solution 5 mg/mL (IV, IM, SC)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to pyridostigmine or other anticholinesterases
Mechanical gastrointestinal or urinary obstruction
Peritonitis
Severe bradycardia or hypotension
Concurrent use with depolarizing neuromuscular blocking agents (e.g., succinylcholine)

Warnings & Clinical Precautions:

Use with caution in animals with asthma, cardiac disease, epilepsy, or hyperthyroidism.
May exacerbate signs of cholinergic toxicity; atropine should be available as an antidote.
In myasthenia gravis, overdosing can cause cholinergic crisis, which may be difficult to distinguish from myasthenic crisis.
Use with caution in animals with renal impairment; dose adjustment may be needed.
In horses, monitor for signs of colic or diarrhea.
In food animals, observe withdrawal times.
Do not use in animals with known hypersensitivity.
Use with caution in pregnant or lactating animals; safety not established.

Adverse Effects & Reactions

Common:

Salivation
Lacrimation
Urination
Defecation
Gastrointestinal cramping
Diarrhea
Vomiting
Bradycardia
Bronchoconstriction
Miosis

Serious / Severe:

Cholinergic crisis (muscle weakness, respiratory depression, collapse)
Severe bradycardia or cardiac arrest
Bronchospasm and respiratory failure
Seizures (rare)

Rare:

Hypersensitivity reactions
Paradoxical muscle weakness
Increased bronchial secretions leading to aspiration

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Atropine	Atropine antagonizes the muscarinic effects of pyridostigmine, used to manage cholinergic side effects.	Moderate
Depolarizing neuromuscular blockers (e.g., succinylcholine)	Pyridostigmine may prolong or enhance the effects of depolarizing blockers.	High
Non-depolarizing neuromuscular blockers (e.g., atracurium, vecuronium)	Pyridostigmine antagonizes the effects of non-depolarizing blockers, used for reversal.	Moderate
Beta-blockers (e.g., propranolol)	May increase the risk of bradycardia and hypotension.	Moderate
Digoxin	May increase the risk of bradycardia.	Moderate
Corticosteroids	May alter the response to pyridostigmine; dose adjustments may be needed.	Mild
Aminoglycoside antibiotics (e.g., gentamicin)	May antagonize the effects of pyridostigmine, reducing its efficacy.	Moderate
Magnesium sulfate	May antagonize the effects of pyridostigmine.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Excessive salivation
Lacrimation
Urination
Defecation
Vomiting
Diarrhea
Muscle fasciculations
Weakness
Bradycardia
Hypotension
Bronchoconstriction
Respiratory distress
Seizures
Collapse
Coma

Emergency Treatment Protocol: Immediate administration of atropine sulfate (0.02-0.05 mg/kg IV, IM, or SC) to counteract muscarinic effects. Supportive care including oxygen therapy, fluid therapy, and respiratory support may be necessary. Monitor cardiac and respiratory function closely. In severe cases, pralidoxime (2-PAM) may be used to reactivate acetylcholinesterase, but it is less effective for carbamates like pyridostigmine. Symptomatic and supportive treatment is essential.

Food Animal Withdrawal Times

🥩 Meat: 7 days🥛 Milk: 3 days

Withdrawal times are not established for pyridostigmine in food animals. Use in food animals should be under veterinary supervision and follow extra-label drug use regulations. The values provided are estimates based on similar drugs; consult regulatory authorities for specific guidance.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, 68-77°F).

Handling & Special Conditions: Protect from moisture. Keep container tightly closed. Do not freeze.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Pyridostigmine is approved for human use, but not specifically approved for veterinary use in most species. It may be used off-label in animals under veterinary supervision.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is permitted under AMDUCA with a valid veterinary-client-patient relationship. However, withdrawal times must be extended and determined by the veterinarian. Pyridostigmine is not approved for use in food animals, so extra-label use requires careful consideration of residue risks.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Pyridostigmine bromide is primarily used in veterinary medicine for the management of myasthenia gravis, particularly in dogs. It is a reversible acetylcholinesterase inhibitor that increases acetylcholine at the neuromuscular junction, improving muscle strength. Dosing must be individualized, starting at the low end and titrating to effect while monitoring for adverse cholinergic effects. Atropine should be available to manage overdosage. In cases of myasthenic crisis, it is crucial to differentiate between myasthenic crisis (under-treatment) and cholinergic crisis (over-treatment); edrophonium testing may be used. Pyridostigmine is also used to reverse non-depolarizing neuromuscular blockade in surgical settings, but this is less common in veterinary practice. Due to its poor oral bioavailability, doses are relatively high. Adverse effects are primarily due to muscarinic stimulation and can be managed with atropine. In food animals, withdrawal times must be observed, and extra-label use should be carefully considered. Overall, pyridostigmine is a valuable drug for managing myasthenia gravis in companion animals, but requires careful monitoring and dose adjustment.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)